Thiazolidinediones could improve endothelial dysfunction and risk of premature coronary heart disease in HIV-infected patients

Journal of Cardiovascular Pharmacology and Therapeutics

Volumn 7, Issue 4, 2002, Pages 207-210

  Carrillo Jimenez, Rodolfo ^a   Lamas, Gervasio A ^a,b   Hennekens, Charles H ^a,b  

^a MOUNT SINAI MEDICAL CENTER   (United States)

^b UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

Author keywords

Endothelium; Insulin resistance; Lipodystrophic syndrome; Protease inhibitors

Indexed keywords

CYTOKINE; PIOGLITAZONE; PROTEINASE INHIBITOR; ROSIGLITAZONE; SULFONYLUREA DERIVATIVE; THIAZOLIDINE DERIVATIVE; 2,4 THIAZOLIDINEDIONE; 2,4 THIAZOLIDINEDIONE DERIVATIVE; 2,4-THIAZOLIDINEDIONE; THIAZOLE DERIVATIVE;

ATHEROGENESIS; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CELL PROLIFERATION; CORONARY STENT; CYTOKINE RELEASE; DYSLIPOPROTEINEMIA; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERTENSION; INFLAMMATION; INSULIN RESISTANCE; ISCHEMIC HEART DISEASE; LIPODYSTROPHY; ORAL GLUCOSE TOLERANCE TEST; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REVIEW; VASCULAR SMOOTH MUSCLE; ANIMAL; CORONARY ARTERY DISEASE; DRUG EFFECT; PATIENT; RISK FACTOR; STATISTICS; VASCULAR ENDOTHELIUM;

ANIMALS; CORONARY DISEASE; ENDOTHELIUM, VASCULAR; HIV INFECTIONS; HUMANS; PATIENTS; RISK FACTORS; THIAZOLES; THIAZOLIDINEDIONES;

EID: 0036818662     PISSN: 10742484     EISSN: None     Source Type: Journal    
DOI: 10.1177/107424840200700402     Document Type: Review

References (24)

1. Passalaris JD, Sepkowitz KA, Glesby MJ. Coronary artery disease and human immunodeficiency virus infection. Clin Infect Dis 31:787-797, 2000
2. Chi D, Henry J, Kelley J, et al. The effects of HIV infection on endothelial function. Endothelium 7(4):223-242, 2000
3. Periard D, Telenti A, Sudre P, et al. Atherogenic dyslipidemia in HIV-infected individuals treated with protease inhibitors. The Swiss HIV cohort study. Circulation 100(7):700-705, 1999
4. Stein JH, Klein MA, Bellehumeur JL. Use of human immunodeficiency virus-1 protease inhibitors is associated with atherogenic lipoprotein changes and endothelial dysfunction. Circulation 104(3):257-262, 2001
5. Vigoroux C, Gharakhanian S, Salhi Y, et al. Diabetes, insulin resistance and dyslipidemia in Iipodystrophic HIV-infected patients on highly active antiretroviral therapy (HAART). Diab Metab 25(3):225-232, 1999
6. Walli R, Herfort O, Michl GM, et al. Treatment with protease inhibitors associated with peripheral insulin resistance and impaired oral glucose tolerance in HIV-1-infected patients. AIDS 12(15):F 167-173, 1998
7. Rickerts V, Brodt H, Staszewski S, Stille W. Incidence of myocardial infarctions in HIV-infected patients between 1983 and 1998: The Frankfurt HIV-cohort study. Eur J Med Res 5(8):329-333, 2000
8. Holmberg S, Moorman A, Tong T, Ward D, Wood K, Greenberg AE, et al. Protease inhibitor use and adverse cardiovascular outcomes in ambulatory HIV patients [abstract 91]. In: 9th Conference on Retroviruses and Opportunistic Infections: Programs and Abstracts (Seattle, WA). Alexandria, VA: Foundation for Retroviruses and Human Health, 2002
9. Friedl AC, Jost CH, Schalcher C, Amann FW, Flepp M, Jenni R, Linka A, Weber R. Acceleration of confirmed coronary artery disease among HIV-infected patients on potent antiretroviral therapy. AIDS 14(17):2790-2792, 2000
10. Wilson PW, Kannel WB, Silbershatz H, D'Agostino RB. Clustering of metabolic factors and coronary heart disease. Arch Int Med 159(10):1104-1109, 1999
11. Komers R, Vrana A. Thiazolidinediones - Tools for the research of metabolic syndrome X. Physiol Res 47(4):215-225, 1998
12. Parulkar AA, Pendergrass ML, Granda-Ayala R, Lee TR, et al. Nonhypoglycemic effects of thiazolidinediones. Ann Int Med 134(1):61-71, 2001
13. Berger J, Moller DE. The mechanisms of action of PPARs. Ann Rev Med 53:409-435, 2002
14. Ziouzenkova O, Perrey S, Marx N, et al. Peroxisome Proliferator-activated Receptors. Curr Ather Rep 4(1): 59-64, 2002
15. Fukunaga Y. Itoh H, Doi K, Tanaka T, et al. Thiazo-Iidinediones, peroxisome proliferator-activated receptor gamma agonists, regulate endothelial cell growth and secretion of vasoactive peptides. Atherosclerosis 158(1): 113-119, 2001
16. Takagi T, Akasaka T, Yamamuro A, et al. Troglitazone reduces neointimal tissue proliferation after coronary stent implantation in patients with non-insulin dependent diabetes mellitus. J Am Coll Cardiol 36(5):1529-1535, 2000
17. Koshiyama H, Shimono D, Kuwamura N, et al. Rapid communication: Inhibitory effect of pioglitazone on carotid arterial wall thickness in type 2 diabetes. J Clin Endo Metab 86(7):3452-3456, 2001
18. Hattori Y, Hattori S, Kasai K. Troglitazone upregulates nitric oxide synthesis in vascular smooth muscle cells. Hypertension 33(4):943-948, 1999
19. Walli R, Michl GM, Muhlbayer D, Brinkmann L, Goebel FD. Effects of troglitazone on insulin sensitivity in HIV-infected patients with protease inhibitor-associated diabetes mellitus. Res Exp Med 199(5):253-262, 2000
20. Kato K, Satoh H, Endo Y, Yamada D. Thiazolidinediones down-regulate plasminogen inhibitor type I expression in human vascular endothelial cells: A possible role for PPARgamma in endothelial function. Biochem Biophys Res Comm 258(2):431-435, 1999
21. Hirose H, Kawai T, Yamamoto Y, et al. Effects of pioglitazone on metabolic parameters, body fat distribution, and serum adiponectin levels in Japanese male patients with type 2 diabetes. Metab Clin Exp 51(3):314-317, 2002
22. Goud C, Pitt B, Webb RC, Richey JM. Synergistic actions of insulin and troglitazone on contractility in endotheliumdenuded rat aortic rings. Am J Physiol 275(5 Pt 1):E882-887, 1998
23. Gabriely I, Wozniak R, Hawkins M, Shamoon H. Troglitazone amplifies counterregulatory responses to hypoglycemia in nondiabetic subjects. J Clin Endo Metab 86(2):521-528, 2001
24. Hadigan C, Corcoran C, Basgoz N, Davis B, Sax P. Grinspoon S. Metformin in the treatment of HIV lipodystrophy syndrome: A randomized controlled trial JAMA. 284(4):472-477, 2000